President Trump endorsed psilocybin and ibogaine in remarks that immediately became the day's most-shared political clip, asking — apparently in earnest — "Can I have some, please?" The statement landed at a moment when both substances are at the leading edge of a genuine revolution in psychiatric treatment.
Psilocybin, the active compound in so-called "magic mushrooms," and ibogaine, a psychedelic derived from an African plant, have been the subject of intensive clinical research for over a decade. Both show remarkable promise for PTSD, depression, and addiction — ibogaine in particular has shown striking results in treating opioid dependence, a crisis that has defined American public health policy for a generation.
The political trajectory of psychedelic medicine is, by any historical measure, extraordinary. A decade ago, psilocybin was a Schedule I controlled substance with no acknowledged medical value. It is now in clinical trials at major research universities, holds FDA Breakthrough Therapy designation, and is the subject of legislation in multiple states. The president of the United States asking to try it on camera is not where most observers predicted this story ending up.
What Trump's endorsement means in policy terms remains unclear. Presidential enthusiasm is not a regulatory pathway. But given the administration's recent executive orders on ibogaine research for veterans, the comments may signal something more substantive than a joke.
Whether the president gets his psilocybin is a matter for his doctor. Whether the federal government accelerates its review of psychedelic medicine is a matter for everyone else.